IN8BIO Reports Promising Survival Data for DeltEx DRI Cells in Glioblastoma Trial

Reuters

11/25

IN8BIO Reports Promising Survival Data for DeltEx DRI Cells in Glioblastoma Trial

IN8BIO Inc. has announced new clinical data from its investigator-sponsored Phase 1 trial of INB-200 and Company-sponsored Phase 2 trial of INB-400 for the treatment of newly diagnosed glioblastoma. The results were presented in poster and oral sessions at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting on November 21 and 22, 2025. Across both trials, 17 patients were treated with the Company's DeltEx DRI gamma-delta T cells, with 14 patients receiving repeated doses. These patients achieved a median progression-free survival of 13.0 months, compared to 6.6 months for 10 patients who received only the standard-of-care Stupp protocol. Median overall survival for patients treated with repeated DeltEx DRI doses has not yet been reached and was reported at 16.4+ months as of October 31, 2025, while the standard-of-care group had a median overall survival of 11.0 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-292057), on November 24, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2586496697"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2586496697\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2586496697?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-25 00:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586496697","market":"us","top_or_hot":-1,"title":"IN8BIO Reports Promising Survival Data for DeltEx DRI Cells in Glioblastoma Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IN8BIO Reports Promising Survival Data for DeltEx DRI Cells in Glioblastoma Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IN8BIO Inc. has announced new clinical data from its investigator-sponsored Phase 1 trial of INB-200 and Company-sponsored Phase 2 trial of INB-400 for the treatment of newly diagnosed glioblastoma. The results were presented in poster and oral sessions at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting on November 21 and 22, 2025. Across both trials, 17 patients were treated with the Company's DeltEx DRI gamma-delta T cells, with 14 patients receiving repeated doses. These patients achieved a median progression-free survival of 13.0 months, compared to 6.6 months for 10 patients who received only the standard-of-care Stupp protocol. Median overall survival for patients treated with repeated DeltEx DRI doses has not yet been reached and was reported at 16.4+ months as of October 31, 2025, while the standard-of-care group had a median overall survival of 11.0 months.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-292057), on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IN8BIO Reports Promising Survival Data for DeltEx DRI Cells in Glioblastoma Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIN8BIO Reports Promising Survival Data for DeltEx DRI Cells in Glioblastoma Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-25 00:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IN8BIO Reports Promising Survival Data for DeltEx DRI Cells in Glioblastoma Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IN8BIO Inc. has announced new clinical data from its investigator-sponsored Phase 1 trial of INB-200 and Company-sponsored Phase 2 trial of INB-400 for the treatment of newly diagnosed glioblastoma. The results were presented in poster and oral sessions at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting on November 21 and 22, 2025. Across both trials, 17 patients were treated with the Company's DeltEx DRI gamma-delta T cells, with 14 patients receiving repeated doses. These patients achieved a median progression-free survival of 13.0 months, compared to 6.6 months for 10 patients who received only the standard-of-care Stupp protocol. Median overall survival for patients treated with repeated DeltEx DRI doses has not yet been reached and was reported at 16.4+ months as of October 31, 2025, while the standard-of-care group had a median overall survival of 11.0 months.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-292057), on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL2dt6fH:1","article_id":"2586496697","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586496697","pubTimestamp":1764001031,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"IN8BIO Inc. has announced new clinical data from its investigator-sponsored Phase 1 trial of INB-200 and Company-sponsored Phase 2 trial of INB-400 for the treatment of newly diagnosed glioblastoma. The results were presented in poster and oral sessions at the 2025 Society for Neuro-Oncology  Annual Meeting on November 21 and 22, 2025. Across both trials, 17 patients were treated with the Company's DeltEx DRI gamma-delta T cells, with 14 patients receiving repeated doses. These patients achieved a median progression-free survival of 13.0 months, compared to 6.6 months for 10 patients who received only the standard-of-care Stupp protocol. Median overall survival for patients treated with repeated DeltEx DRI doses has not yet been reached and was reported at 16.4+ months as of October 31, 2025, while the standard-of-care group had a median overall survival of 11.0 months.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","INAB":"IN8bio, Inc.","BK4539":"次新股"},"translate_title":"IN8BIO报告DeltEx DRI细胞在胶质母细胞瘤试验中有希望的存活数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INAB":0.9},"content_text":"IN8BIO Reports Promising Survival Data for DeltEx DRI Cells in Glioblastoma Trial\n    \n\n        IN8BIO Inc. has announced new clinical data from its investigator-sponsored Phase 1 trial of INB-200 and Company-sponsored Phase 2 trial of INB-400 for the treatment of newly diagnosed glioblastoma. The results were presented in poster and oral sessions at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting on November 21 and 22, 2025. Across both trials, 17 patients were treated with the Company's DeltEx DRI gamma-delta T cells, with 14 patients receiving repeated doses. These patients achieved a median progression-free survival of 13.0 months, compared to 6.6 months for 10 patients who received only the standard-of-care Stupp protocol. Median overall survival for patients treated with repeated DeltEx DRI doses has not yet been reached and was reported at 16.4+ months as of October 31, 2025, while the standard-of-care group had a median overall survival of 11.0 months.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-292057), on November 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}